On the other hand, when other hypothesis dealing with the onset and progression of AD have been postulated like Aβ and tau hypothesis, it is evident that pharmacodynamics and pharmacokinetic properties of ChEIs are not sufficient to tackle AD. This evidence concerns the gene MAPT and Alzheimer disease.